1,127 results on '"Parving, H H"'
Search Results
2. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)
3. Insulin analogues and severe hypoglycaemia in type 1 diabetes
4. Effect of insulin degludec vs insulin glargine U100 on occurrence of nocturnal hypoglycaemia assessed by plasma glucose profiles in people with type 1 diabetes: HypoDeg trial
5. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes
6. Effect of insulin degludec versus insulin glargine u100 on occurrence of cgm-recorded nocturnal hypoglycaemia in people with type 1 diabetes and previous nocturnal severe hypoglyceamia
7. ACTH stimulation test in patients with type 1 diabetes and recurrent severe hypoglycaemia
8. The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1
9. Supplement to: Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
10. Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study
11. SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes
12. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials
13. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
14. A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus
15. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes
16. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial
17. Telomere length predicts all-cause mortality in patients with type 1 diabetes
18. The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers
19. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial
20. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy
21. Long-term prevention of diabetic nephropathy: an audit
22. Increased renal gene transcription of protein kinase C-β in human diabetic nephropathy: relationship to long-term glycaemic control
23. Comparison of Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Severe Nocturnal Hypoglycaemia
24. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes
25. Anaemia in diabetes: is there a rationale to TREAT?
26. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients
27. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
28. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications
29. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy
30. Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate
31. Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3‐deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub‐study
32. Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes
33. Total plasma homocysteine is associated with hypertension in Type I diabetic patients
34. Controlling hypertension in diabetes
35. Pregnancy and progression of diabetic nephropathy
36. Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in Type I diabetic patients
37. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study
38. Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes
39. Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy
40. Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy
41. Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme
42. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril
43. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment
44. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
45. Glomerular hyperfiltration in microalbuminuric NIDDM patients
46. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy
47. Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy—a prospective follow-up study
48. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality
49. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes
50. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.